Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
olanzapine-RAIM · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| olanzapine-RAIM | DRUG | - |
| placebo | DRUG | - |
Inclusion Criteria: * Patients must have schizophrenia that meets disease diagnostic criteria in DSM-IV-TR * Patients must be inpatients during the study * Patients must have a minimum total score of no less than 14 on the five items of the PANSS-EC and at least one individual item score of no less...
Top 15 of 16 competitors
Olanzapine-RAIM is an investigational rapid acting intramuscular formulation of olanzapine developed by Eli Lilly and Company. It is being studied for the treatment of agitation in patients with schizophrenia. It is a small molecule therapy and remains in clinical development rather than being an approved product.
Olanzapine-RAIM is being studied for agitation in patients with schizophrenia. The Phase 2 trial enrolled agitated patients with schizophrenia, and the formulation is designed for intramuscular administration. The program is investigational, and the studied use is specifically agitation in the schizophrenia population rather than schizophrenia maintenance treatment.
Olanzapine-RAIM is developed by Eli Lilly and Company, which trades under the ticker LLY. Lilly is the sponsor of the clinical program evaluating this rapid acting intramuscular olanzapine formulation in agitated patients with schizophrenia.
Olanzapine-RAIM is in Phase 2 development. The program has one completed Phase 2 trial, and no active trials are currently listed. It is an investigational product and has not been established as an approved treatment.
Olanzapine-RAIM has been evaluated in one completed Phase 2 trial, NCT00316238, titled A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia. The trial enrolled 160 patients in Japan, was randomized and double blind, and included participants aged 20 years and older.